TBR-760

Tiburio is developing TBR-760, a dopamine-somatostatin chimeric compound, for the treatment of non-functioning pituitary adenoma (NFPA).

Tiburio is developing TBR-760, a dopamine-somatostatin chimeric compound, for the treatment of non-functioning pituitary adenoma (NFPA).

TBR-760 is a potential breakthrough in the treatment of NFPA. TBR-760 is a subcutaneously administered compound that binds to both dopamine and somatostatin receptors. It is designed to inhibit NFPA cell proliferation with the potential to shrink or halt tumor growth.

Tiburio expects to move TBR-760 into a Phase 2 clinical trial in patients with NFPA in the second half of 2020.

PreclinicalPhase 1Phase 2Phase 3
Preclinical
Phase 1
Phase 2
Phase 3